OS07.1 Molecular differences in IDH wild type glioblastoma according to MGMT promoter methylation status

Background: O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a biomarker for patients with glioblastoma treated with alkylating agents. We investigated whether this marker just predicts the efficacy of alkylating chemotherapy or defines a molecularly distinct tumor subpop...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Kessler, T., Sahm, F., Sadik, A., Hertenstein, A., Bendszus, M., von Deimling, A., Platten, M., Wick, W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
ORAL PRESENTATIONS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5463725/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox036.042
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller